| Du S, Zhang Y, Hao R, Qiu L, Li C, Li Y, Liu RR, Zhao CH, Li J, Ye S, Zhou J, Li Y, Yi Q, Zhang S, Sun M, Luo T, Xu J. Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity. Mol Cancer Ther. 2026 May 4;25(5):701-716. doi: 10.1158/1535-7163.MCT-25-0171. PMID: 41208285. |
30